Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
420
First IPO Date
May 31, 2013
| Name | Title | Pay | Year Born |
| Amir London | Chief Executive Officer | 714,000 | 1969 |
| David Tsur | Co-Founder & Independent Deputy Chairman of the Board | 252,000 | 1950 |
| Jon R. Knight | Vice President of US Commercial Operations | 308,000 | 1966 |
| Boris Gorelik | Vice President of Business Development & Strategic Programs | 422,000 | 1982 |
| Eran Nir | Chief Operating Officer | 468,000 | 1973 |
| Chaime Orlev | Chief Financial Officer | 506,000 | 1970 |
| Nir Livneh | Vice President, General Counsel & Corporate Secretary | 0 | 1979 |
| Hanni Neheman | Vice President of Marketing & Sales | 0 | 1970 |
| Liron Reshef | Vice President of Human Resources | 0 | 1972 |
| Shavit Beladev | Vice President of Kamada Plasma | 0 | 1971 |
Kamada Ltd. is a biopharmaceutical firm focused on developing, manufacturing, and distributing protein therapeutics derived from human plasma. The company operates through two core business areas: its proprietary product segment and its distribution division. Its own manufactured portfolio includes KAMRAB/KEDRAB for rabies prevention, CYTOGAM to prevent cytomegalovirus disease in transplant recipients, WINRHO SDF for immune thrombocytopenic purpura and Rhesus (Rh) isoimmunization, HEPAGAM B for hepatitis B recurrence prevention following liver transplants and for post-exposure prophylaxis, VARIZIG for post-exposure chickenpox prophylaxis, and GLASSIA for intravenous alpha-1 antitrypsin deficiency (AATD). Kamada also produces KamRho (D) for the prophylaxis of hemolytic disease of newborns and immune thrombocytopenic purpura, along with a specific antiserum for Vipera palaestinae and Echis coloratus snake bites. Additionally, the company distributes a wide array of third-party pharmaceutical products, encompassing treatments like BRAMITOB for chronic pulmonary infections, FOSTER for asthma, PROVOCHOLINE for diagnosing bronchial airway hyperactivity, and specialized therapies such as IVIG for immunodeficiency, VARITECT for chickenpox and zoster herpes, and various factors for hemophilia A and B, among numerous others for conditions like hepatitis B, cytomegalovirus, angioedema, Japanese encephalitis, and prostate cancer. Kamada markets its offerings in the United States through strategic partners and internationally via a network of distributors. The company maintains significant collaborations with Takeda Pharmaceuticals Company Limited, PARI GmbH, and Kedrion Biopharma. Established in 1990, Kamada Ltd. is headquartered in Rehovot, Israel.